GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lyra Therapeutics Inc.
Lyra Therapeutics develops drugs for the treatment of ear, nose, and throat diseases. Its stock price is a classic biotech story, with its trajectory determined by clinical trial results and FDA approvals for its key products.
Share prices of companies in the market segment - Pharma other
Lyra Therapeutics develops drugs for the treatment of chronic rhinosinusitis using its technology platform for deep sinus delivery. We've classified it in "Other Pharmaceuticals." The chart below shows how investors value companies working in the ENT field.
Broad Market Index - GURU.Markets
Lyra Therapeutics is a biopharmaceutical company developing treatments for ear, nose, and throat diseases using its drug delivery technology. Its unique niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Lyra compares to it.
Change in the price of a company, segment, and market as a whole per day
LYRA - Daily change in the company's share price Lyra Therapeutics Inc.
Lyra Therapeutics, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its rhinosinusitis treatments.
Daily change in the price of a set of shares in a market segment - Pharma other
Lyra Therapeutics is a pharmaceutical company, and its volatility depends on clinical trial results and regulatory decisions. The chart below shows average daily fluctuations in this sector. It helps assess how LYRA's risk profile compares to industry standards.
Daily change in the price of a broad market stock, index - GURU.Markets
Lyra Therapeutics is a pharmaceutical company developing drugs to treat respiratory diseases. Its shares, like many in the sector, are volatile and react to news about clinical trials. These movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lyra Therapeutics Inc.
For Lyra Therapeutics, Inc., the year-over-year trend is a story about the development of its drug delivery platform for chronic rhinosinusitis. Its 12-month market cap is entirely dependent on clinical trial data. The success of its implant, which releases drugs over several months, could offer a new treatment paradigm.
Annual dynamics of market capitalization of the market segment - Pharma other
Lyra Therapeutics, Inc. is a biotechnology company developing drugs for the treatment of ear, nose, and throat diseases. Its unique drug delivery technology is its key advantage. The chart shows how the market views its innovative platform and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lyra Therapeutics, which develops innovative drug delivery methods, is tracking its performance in clinical trials. Its technology can be used to treat a variety of diseases, and investors are evaluating its potential. Its stock performance is driven entirely by research data, not market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lyra Therapeutics Inc.
Lyra Therapeutics is a late-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its chronic rhinosinusitis treatments is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Pharma other
Lyra Therapeutics, Inc. is a biopharmaceutical company developing a new treatment for chronic rhinosinusitis using its therapeutic matrix, which delivers drugs directly to tissue. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its unique approach to treating this common condition in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of sinus conditions. Its shares are buoyed by anticipation of clinical trial results. Their monthly performance is completely disconnected from the market, as the chart clearly illustrates, showing the reaction to scientific data rather than general trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lyra Therapeutics Inc.
Lyra Therapeutics develops new drug delivery methods for ear, nose, and throat diseases. Its weekly stock price is volatile and depends on progress in its clinical programs and FDA decisions.
Weekly dynamics of market capitalization of the market segment - Pharma other
Lyra Therapeutics develops drugs for the treatment of sinus conditions. The chart compares the weekly stock performance of this niche company with the broader pharmaceutical sector. Does its niche allow it to chart a trajectory independent of global industry trends?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lyra Therapeutics is a pharmaceutical company whose stock moves to the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
LYRA - Market capitalization of the company Lyra Therapeutics Inc.
The Lyra Therapeutics chart tells the story of a new drug delivery method. Its market cap reflects investor confidence in its implant technology for treating chronic rhinosinusitis. Its dynamics reflect how the market views the clinical trial results and commercial potential of this approach.
LYRA - Share of the company's market capitalization Lyra Therapeutics Inc. within the market segment - Pharma other
Lyra Therapeutics is developing a new form of drug delivery for the treatment of chronic rhinosinusitis, implanting the drug directly into the nasal cavity. In the pharmaceutical sector, its market capitalization reflects the innovative nature of this approach. The company's size reflects a bet that its technology will provide more effective and long-lasting treatment than traditional sprays and tablets.
Market capitalization of the market segment - Pharma other
Lyra Therapeutics develops drugs for ear, nose, and throat conditions. How big is this niche? The chart below shows the overall market capitalization of this pharmaceutical sector. Its dynamics reflect the need for new, more effective treatments for chronic sinusitis and other common ENT conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Lyra Therapeutics chart shows how the market is valuing a new drug delivery technology for chronic rhinosinusitis. The company's market cap is based on its implants, which release the drug over several months. This chart illustrates how innovations can change the treatment of common conditions.
Book value capitalization of the company, segment and market as a whole
LYRA - Book value capitalization of the company Lyra Therapeutics Inc.
Lyra Therapeutics' book value is its tangible assets, which include the rights to its XTreo™ drug delivery platform and financial reserves for clinical trials. The chart below shows how this scientific and financial capital has changed over time for the treatment of ear, nose, and throat diseases.
LYRA - Share of the company's book capitalization Lyra Therapeutics Inc. within the market segment - Pharma other
Lyra Therapeutics, Inc. is developing a new technology for drug delivery to ENT organs. Its tangible assets include its own GMP manufacturing facilities for creating its unique implantable matrices. The chart shows the company's control over this specialized pharmaceutical infrastructure.
Market segment balance sheet capitalization - Pharma other
Lyra Therapeutics is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Lyra focuses on drug development, and its capital comes from its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Lyra Therapeutics' assets are not factories, but rather technology and pilot production for the creation of biodegradable implants that deliver medications directly to the sinuses for the treatment of chronic rhinosinusitis. Its book value reflects its scientific and manufacturing potential.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lyra Therapeutics Inc.
Lyra Therapeutics develops drugs for the treatment of chronic rhinosinusitis. Its value lies in its drug delivery technology, which ensures sustained drug release. The chart shows how the market views its clinical data and commercial prospects.
Market to book capitalization ratio in a market segment - Pharma other
Lyra Therapeutics develops drugs to treat ear, nose, and throat conditions using its drug delivery technology. The chart shows how the market values its unique approach and the commercial potential of its products compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Lyra Therapeutics develops new drug delivery methods. Its intellectual property and clinical trial data are its main assets. This chart illustrates how the market values innovative pharmaceutical platforms that can improve the effectiveness of existing drugs.
Debts of the company, segment and market as a whole
LYRA - Company debts Lyra Therapeutics Inc.
Lyra Therapeutics develops drugs using its proprietary technology to deliver drugs directly to the site of disease, such as the sinuses. Developing this platform and conducting clinical trials for specific products requires significant capital. This chart shows how the company funds its unique R&D programs.
Market segment debts - Pharma other
Lyra Therapeutics is a biotech company developing drugs for the treatment of ear, nose, and throat diseases using its drug delivery technology. This chart shows its financial position at the clinical development stage and its dependence on external funding.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lyra Therapeutics Inc.
Lyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases. This chart shows its financial structure. For a company in the clinical trials stage, debt is a significant burden, increasing financial risks in the event of delays or failures in the trials.
Market segment debt to market segment book capitalization - Pharma other
Lyra Therapeutics is developing a new drug delivery system for chronic rhinosinusitis, implanting the drug directly into the sinuses. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how the company finances its innovative, yet capital-intensive, clinical research.
Debt to book value of all companies in the market
Lyra Therapeutics, Inc. is developing a novel drug delivery technology for the treatment of ear, nose, and throat diseases. Currently in clinical trials, the company relies on investor capital. This chart, reflecting the debt of established businesses, emphasizes that Lyra's funding is a bet on the success of its unique platform, not on current cash flow.
P/E of the company, segment and market as a whole
P/E - Lyra Therapeutics Inc.
For Lyra Therapeutics, a biopharmaceutical company developing drugs for ear, nose, and throat diseases, the P/E ratio is not applicable. The company has no profit. Its valuation is based on its unique drug delivery technology and the success of its products in clinical trials.
P/E of the market segment - Pharma other
Lyra Therapeutics is a clinical-stage biopharmaceutical company developing treatments for ear, nose, and throat diseases using its proprietary drug delivery technology. This chart shows the average valuation for the sector, helping to understand how the market values this niche pharmaceutical company.
P/E of the market as a whole
Lyra Therapeutics is a biopharmaceutical company developing treatments for ear, nose, and throat diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lyra Therapeutics Inc.
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its therapeutic matrix, which delivers medication directly to the sinuses. This schedule reflects clinical trial expectations. Evaluation depends on the potential for long-term treatment without the need for surgical intervention.
%20P%2FE%20Lyra%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lyra-Therapeutics-Inc.&v=1772695870746 "Chart of the company's future (projected) P/E Lyra Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma other
Lyra Therapeutics develops drugs for the treatment of chronic rhinosinusitis using its drug delivery technology. Its valuation relative to other pharmaceutical companies reflects investor sentiment about its unique approach, demonstrating the market's confidence in its ability to offer more effective and convenient treatments to millions of patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772695870764 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its proprietary drug delivery technology. The company is in late-stage clinical trials. This chart illustrates the overall healthcare market sentiment that influences the valuation of biotech companies approaching the potential launch of their first product.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772695870768 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lyra Therapeutics Inc.
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its implant technology, which delivers medication directly to the sinuses. Financial results presented here are dependent on the success of clinical trials and potential approval of this new approach.
Profit of companies in the market segment - Pharma other
Lyra Therapeutics develops drugs for ear, nose, and throat (ENT) diseases using its drug delivery platform. This chart shows the overall profitability of the pharmaceutical industry. It helps assess the potential commercial success of niche therapeutic areas such as ENT.
Overall market profit
Lyra Therapeutics develops drugs for the treatment of chronic rhinosinusitis using a proprietary drug delivery technology. It's a niche pharmaceutical company. The company's success depends on the results of clinical trials and commercialization. Economic cycles, as seen in this chart, have virtually no impact on the company.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lyra Therapeutics Inc.
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its proprietary drug delivery technology. The company's future revenue depends on the success of its lead product in clinical trials. This chart shows analyst expectations for the commercial potential of this innovative treatment.
%20profit%20of%20the%20company%20Lyra%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lyra-Therapeutics-Inc.&v=1772695870852 "Graph of future (projected) profit of the company Lyra Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its technology, which delivers sustained drug release directly into the nasal cavity. This chart shows forecasts for the pharmaceutical sector. It helps assess how innovative delivery systems can improve the treatment of common conditions and carve out a niche in the market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772695870865 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
For Lyra Therapeutics, a biopharmaceutical company, this schedule is important for the investment climate. Expectations of economic growth make it easier to raise the capital needed to conduct expensive clinical trials and bring new drugs to market. During downturns, investors are more cautious.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772695870890 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lyra Therapeutics Inc.
Lyra Therapeutics develops drugs to treat ear, nose, and throat conditions. This chart shows how investors view its scientific platform and the potential revenue that could be generated upon approval.
P/S market segment - Pharma other
Lyra Therapeutics develops drugs for ear, nose, and throat (ENT) conditions using its extended-release technology. This chart shows the average valuation in the pharmaceutical sector. It helps understand how investors view Lyra's innovative approach to treating chronic rhinosinusitis.
P/S of the market as a whole
Lyra Therapeutics, Inc. is a biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases using its drug delivery technology. Its lead candidate targets chronic rhinosinusitis. Future revenue is dependent on clinical success. This chart provides context for assessing the risks and potential of biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lyra Therapeutics Inc.
Lyra Therapeutics develops drugs for the treatment of ear, nose, and throat diseases using its drug delivery technology. Future revenue depends on the success of its lead candidate in clinical trials. The chart shows the market's estimate of the potential sales volume of its products.
%20P%2FS%20Lyra%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lyra-Therapeutics-Inc.&v=1772695870949 "The graph of the company's future (projected) P/S Lyra Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma other
Lyra Therapeutics is developing drugs to treat chronic rhinosinusitis using its biosoluble matrix technology, which delivers medication directly to the sinuses over several months. This chart shows how investors view the potential of this innovative treatment approach.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772695870961 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
This reflects the overall sentiment of pharmaceutical investors. For Lyra Therapeutics, a company developing extended-release medications for sinus conditions, this indicates demand for more convenient forms of therapy. Market optimism supports innovations that could replace daily medications with a single treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772695870983 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lyra Therapeutics Inc.
Lyra Therapeutics develops therapeutics for ear, nose, and throat conditions using its drug delivery technology, which provides sustained release. This graph will reflect the revenue from sales of its products following their approval. This growth will indicate the success of its new approach to treating chronic rhinosinusitis.
Sales of companies in the market segment - Pharma other
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its nasal drug delivery technology. This graph illustrates the dynamics of the pharmaceutical sector. Lyra's innovative approach enables sustained drug release, which could radically change the standard of treatment for this condition.
Overall market sales
Lyra Therapeutics, Inc. develops drugs for the treatment of ear, nose, and throat diseases. Its success depends on clinical trial results and regulatory approval. The overall economic environment, shown in this chart, influences the availability of capital for R&D and the strategic decisions of potential partners.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lyra Therapeutics Inc.
Lyra Therapeutics is developing drugs for the treatment of chronic rhinosinusitis using its technology platform, which provides sustained drug delivery directly into the nasal cavity. This chart shows analysts' expectations for the success of clinical trials and the commercial potential of this new treatment approach.
%20sales%20of%20the%20company%20Lyra%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lyra-Therapeutics-Inc.&v=1772695871128 "Schedule of future (projected) sales of the company Lyra Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma other
Lyra Therapeutics develops drugs to treat ear, nose, and throat conditions using its drug delivery technology. This chart shows expectations for the pharmaceutical sector. It reflects the need for new, more effective treatments for chronic conditions such as rhinosinusitis.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772695871207 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Lyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a novel drug delivery technology for ear, nose, and throat diseases. Its future depends on the success of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital to finance innovative medical technologies that could improve localized therapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772695871222 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lyra Therapeutics Inc.
Lyra Therapeutics is developing a new drug delivery technology for the treatment of sinus conditions. This chart shows the financial status of the company's late-stage clinical trials. Profitability will depend on the successful approval and launch of its product, which could become a new standard in the treatment of chronic rhinosinusitis.
Market segment marginality - Pharma other
Lyra Therapeutics develops drugs for the treatment of chronic rhinosinusitis using its drug delivery technology. For a pharmaceutical company, profitability is determined by product efficacy and market size. This graph shows the average profitability in the industry, allowing one to estimate the commercial success Lyra can expect if approved.
Market marginality as a whole
Lyra Therapeutics is a biopharmaceutical company developing topical treatments for ear, nose, and throat diseases. This overall market profitability chart does not impact its operations. Its potential lies in its unique drug delivery technology, which can provide prolonged drug action directly at the site of the disease.
Employees in the company, segment and market as a whole
Number of employees in the company Lyra Therapeutics Inc.
Lyra Therapeutics is a biotech company developing drugs for ear, nose, and throat diseases using its drug delivery technology. This graph shows the team managing the clinical trials. Their size reflects the stage of development and complexity of the programs.
Share of the company's employees Lyra Therapeutics Inc. within the market segment - Pharma other
Lyra Therapeutics is developing a new drug delivery system for chronic rhinosinusitis, implanting it directly into the nasal cavity. This chart shows the percentage of otolaryngologists, chemists, and biodegradable polymer specialists the company employs. It reflects its concentration of unique expertise in solving a specific medical problem.
Number of employees in the market segment - Pharma other
Lyra Therapeutics is developing a new drug delivery technology for the treatment of chronic rhinosinusitis, implanting the drug directly into the nasal cavity. This graph illustrates how innovations in delivery methods can radically change treatment, requiring scientists and engineers to create new therapeutic systems.
Number of employees in the market as a whole
Lyra Therapeutics is another company operating in the biotech sector. The large number of such companies in the market creates intense competition for capital and talent, but also accelerates overall scientific progress. This graph reflects the combined impact of their activities—thousands of highly skilled jobs in one of the most advanced sectors of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics develops drugs for the treatment of ear, nose, and throat (ENT) diseases using its drug delivery platform. This chart represents the net intellectual capital valuation. The company's value is based on the potential of its technology and drug candidates. The chart shows how highly the market values this scientific IP per scientist.
%20of%20the%20company%20Lyra%20Therapeutics%20Inc.%20(LYRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lyra-Therapeutics-Inc.-LYRA&v=1772695871492 "Chart of market capitalization per employee (in thousands of dollars) of the company Lyra Therapeutics Inc. (LYRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Lyra Therapeutics develops new drug delivery methods for ear, nose, and throat diseases. This is a niche but important area of pharmaceuticals. The chart shows how the market values their focused expertise and technology platform per employee.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772695871539 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Lyra Therapeutics, Inc. is a biopharmaceutical company developing treatments for ear, nose, and throat diseases. This chart reflects the market's perceived value per employee, highlighting the valuation of innovative drug delivery systems.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772695871547 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics is a clinical-stage biotech company with no commercial products. This chart shows the company's net loss per employee. It reflects how much the company invests in each scientist to conduct R&D and clinical trials.
%20Chart%20Lyra%20Therapeutics%20Inc.%20(LYRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lyra-Therapeutics-Inc.-LYRA&v=1772695871570 "Company Profit Per Employee (in thousands of dollars) Chart Lyra Therapeutics Inc. (LYRA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Lyra Therapeutics develops drugs for ear, nose, and throat diseases using its proprietary drug delivery platform. It is a biotech company focused on R&D. The negative earnings per employee, likely shown in this chart, is industry standard and reflects significant investment in its scientific team.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772695871596 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Lyra Therapeutics (LYRA) is a MedTech company developing a drug-delivery platform (implant) for delivering medications to the sinuses for the treatment of chronic rhinosinusitis. This company is engaged in R&D and commercialization of medical devices. This chart shows the market average profitability per employee. It helps assess how effective LYRA's MedTech model (IP) is in generating revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772695871615 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases. This graph shows the path from research to commercialization. An increase in this indicator will indicate successful product launches and the company's ability to monetize its research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lyra-Therapeutics-Inc.-LYRA&v=1772695871769 "Sales chart per company employee Lyra Therapeutics Inc. (LYRA)")
Sales per employee in the market segment - Pharma other
Lyra Therapeutics is a biotech company developing drugs for ear, nose, and throat diseases using its drug delivery platform. This chart shows the average revenue per employee in this segment. It helps evaluate how productive Lyra's R&D and commercialization team is in its niche compared to its competitors.
Sales per employee for the market as a whole
Lyra Therapeutics is a biotech company developing drugs for the treatment of ear, nose, and throat (ENT) diseases using its drug delivery platform. The company has no commercial revenue, which is irrelevant. Their entire value lies in the potential of their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics is developing a drug delivery technology (via implant) for the treatment of chronic rhinosinusitis (the common cold). This chart shows the odds that their product will fail. "Bears" believe their device will fail to prove effective in late-stage trials or will fail to receive FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lyra-Therapeutics-Inc.-LYRA&v=1772695871859 "Short Shares Chart for the Company Lyra Therapeutics Inc. (LYRA)")
Shares shorted by market segment - Pharma other
Lyra Therapeutics, Inc. develops drugs for the treatment of chronic rhinosinusitis (sinus inflammation) using its slow-release drug delivery platform. This indicator reflects the overall volume of short positions in the pharmaceutical sector. An increase in short positions here may indicate that investors see risks in the FDA approval of new drug delivery systems.
Shares shorted by the overall market
Lyra Therapeutics develops drugs to treat chronic rhinosinusitis (sinusitis). It's a niche biotech. This chart measures overall fear. When investors are pessimistic, they are unwilling to take on the "binary" risk of clinical trials. A Phase III failure could wipe out LYRA shares, and during times of fear, this risk seems unacceptable to investors.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics develops drugs to treat chronic rhinosinusitis (sinus inflammation) using its drug delivery platform. This chart tracks how investors view their clinical data, showing "overheated" (above 70) on positive news or "oversold" (below 30) on delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lyra-Therapeutics-Inc.-LYRA&v=1772695871905 "RSI 14 indicator chart for the company's stock Lyra Therapeutics Inc. (LYRA)")
RSI 14 Market Segment - Pharma other
Lyra Therapeutics is a biotech company developing the XTreo platform for delivering drugs directly to the sinuses to treat chronic rhinosinusitis. This chart measures the overall momentum of the biotech sector. It helps separate LYRA's volatility from the overall industry trend.
RSI 14 for the overall market
For Lyra Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LYRA (Lyra Therapeutics Inc.)
Lyra Therapeutics is developing drugs (based on the LYR matrix) for the treatment of chronic rhinosinusitis, delivering medication directly to the sinuses. This chart shows the average analyst forecast. Their targets are based on the clinical trial results of their lead candidates and the potential market size for patients avoiding surgery.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LYRA-Lyra-Therapeutics-Inc.&v=1772695872038 "A chart showing analyst consensus forecasts for the expected stock price. LYRA (Lyra Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price LYRA (Lyra Therapeutics Inc.)
Lyra Therapeutics is a biotech company developing a platform (XTreo) for long-acting drug delivery for ear, nose, and throat (ENT) diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the success of their key R&D programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LYRA-Lyra-Therapeutics-Inc.&v=1772695872054 "A chart showing the difference between the consensus forecast and the actual stock price. LYRA (Lyra Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Lyra Therapeutics is a biotech company transforming sinusitis treatment. It has developed a "matrix" (XTREO) that is implanted in the nose and slowly releases medication. This chart shows analysts' overall expectations across the pharmaceutical sector, reflecting whether experts believe in new "smart" drug delivery systems.
Analysts' consensus forecast for the overall market share price
Lyra Therapeutics (LYRA) is a biopharmaceutical company that has reinvented ENT treatment. They developed a technology that delivers a drug for chronic sinusitis deep into the sinuses and slowly releases it. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D companies solving niche medical problems.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lyra Therapeutics Inc.
Lyra Therapeutics is a nasal spray for sinusitis. They are developing a matrix (LYR-210) that is injected into the nose and slowly (over months) releases a drug (a steroid) directly into the sinuses to treat chronic rhinosinusitis. This graph is purely an indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma other
Lyra Therapeutics (LYRA) specializes in ENT diseases. Their key technology is an implantable matrix (LYR-210), which slowly releases medication directly into the sinuses to treat chronic rhinosinusitis. This graph shows the average index for the segment, helping to assess how this targeted approach compares to the average.
The AKIM Index for the overall market
Lyra Therapeutics is a company that develops implantable drug matrices for the long-term treatment of ear, nose, and throat diseases (chronic sinusitis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical story compares to overall economic trends.
